Dr. Jean-Pierre Bizzari, is an oncologist and pharmaceutical executive with extensive experience in cancer drug development. He studied medicine in France, specializing in oncology, and went on to hold senior positions in leading pharmaceutical companies. Over the course of his career, he played a key role in the clinical development and approval of several landmark oncology therapies, including docetaxel, irinotecan, oxaliplatin and gliadel.

 

Dr. Bizzari has served as Executive Vice President of Clinical Development at Celgene Corporation, where he oversaw the development of innovative treatments for hematologic malignancies and solid tumors, including lenalidomide, pomalidomide and nab-paclitaxel. He has also been actively involved in numerous biotech boards and scientific advisory boards, supporting innovation in cancer research.

 

Widely respected in the oncology community, he is recognized for bridging clinical expertise with strategic drug development, helping to bring transformative therapies to patients worldwide.

​

​